Literature DB >> 10493108

Betaxolol, a beta1-adrenoceptor antagonist, has an affinity for L-type Ca2+ channels.

J Melena1, J P Wood, N N Osborne.   

Abstract

The effect of betaxolol on the specific binding of [3H]diltiazem and [3H]nitrendipine to rat cortical membranes was examined. Betaxolol inhibited specific [3H]diltiazem and [3H]nitrendipine binding with IC50 values of 19.7 and 46.3 microM, respectively. The effect of betaxolol on L-type Ca2+ channels showed little stereospecificity, since similar inhibitions of radioligand binding were observed with both racemic betaxolol and L-betaxolol. The dissociation kinetics of [3H]diltiazem were unaffected by 30 microM betaxolol, whereas it increased the [3H]nitrendipine dissociation rate, thus suggesting that betaxolol directly interacts with the benzothiazepine binding site and allosterically modulates the dihydropyridine binding site. Carteolol, propranolol and timolol were also found to inhibit both specific [3H]diltiazem and [3H]nitrendipine binding to rat cortical membranes, but with less potency than betaxolol. The ability of betaxolol to interact with L-type Ca2+ channels may have a role in its therapeutic effects in the management of systemic hypertension and in reducing neuronal death as occurring in glaucoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493108     DOI: 10.1016/s0014-2999(99)00459-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Zinc and energy requirements in induction of oxidative stress to retinal pigmented epithelial cells.

Authors:  John P M Wood; Neville N Osborne
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

Review 3.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.

Authors:  G Chidlow; J Melena; N N Osborne
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

5.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

6.  Metipranolol attenuates lipid peroxidation in rat brain: a comparative study with other antiglaucoma drugs.

Authors:  José Melena; Neville N Osborne
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-07-29       Impact factor: 3.117

Review 7.  Neuroprotection in glaucoma.

Authors:  Sushil K Vasudevan; Viney Gupta; Jonathan G Crowston
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

8.  Preclinical models to investigate retinal ischemia: advances and drawbacks.

Authors:  Gillipsie Minhas; Ryuichi Morishita; Akshay Anand
Journal:  Front Neurol       Date:  2012-05-11       Impact factor: 4.003

9.  Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells.

Authors:  Zi-Kui Yu; Yi-Ning Chen; Makoto Aihara; Wei Mao; Saiko Uchida; Makoto Araie
Journal:  Mol Vis       Date:  2007-06-11       Impact factor: 2.367

10.  Crystallins are regulated biomarkers for monitoring topical therapy of glaucomatous optic neuropathy.

Authors:  Verena Prokosch; Maurice Schallenberg; Solon Thanos
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.